ArticleEngineering biology
Building Capacity for the Engineering of Biology and Biomanufacturing in Finland.
Article in Engineering biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finland's efforts on engineering biology (synthetic biology) originate from the investments in genetic engineering at the beginning of 1980s. The efforts were linked early on with industry, such as dairy companies, vaccine production and production of ethanol and industrial enzymes, and development of commercial scale bioprocesses. Timely support for activities in metabolic engineering, systems biology and genome wide technologies (omics) and incorporating bioinformatics and cell level modelling evolved the field naturally towards synthetic biology and biofoundry activities. This foundation has created a strong basis in industrial biotechnology in particular, its insights and capabilities being increasingly relevant today within the green transition and bioeconomy contexts. In Finland, more than 830 companies are categorised to operate in biotechnology, collectively producing a turnover of 7.1 billion euros and providing jobs for around 19,400 people. Technology and business opportunities are developing fastest in the field of modern biotechnology rooted in molecular biology. Consequently, in the past 15 years, Finland has evidenced the founding of many new biotechnology firms. In relation to bioeconomy, Finland has also a significant research tradition in plant biotechnology and breeding and in pilot scale cultivation of plant cells. Furthermore, engineering biology activities within medical biotechnology and diagnostics are strong. According to a recent report, 88.5% of the revenue of Finnish biotechnology companies comes from activities classified as industrial biotechnology. This article focuses on engineering/synthetic biology developments for industrial biotechnology, including microbial production of food components and pharma products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.